Bayer AG
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Bill Anderson
- Full Time Employees
- 88,078
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- Kaiser-Wilhelm-Allee 1 Leverkusen NW Germany 51368
- IPO Date
- Nov 18, 1996
- Website
- bayer.com
- Similar Companies
- Business
- Bayer AG is a global life science company headquartered in Leverkusen, Germany, primarily engaged in the healthcare and agriculture sectors. The company operates through three main segments: Pharmaceuticals, Consumer Health, and Crop Science. Its Pharmaceuticals segment develops, manufactures, and markets prescription medicines focusing on cardiology, oncology, hematology, ophthalmology, women's health, and specialized therapies including cell and gene therapies. The Consumer Health division offers over-the-counter products spanning nutritional supplements, allergy relief, cough and cold remedies, dermatology products, pain management, cardiovascular risk prevention, and digestive health. Bayer’s Crop Science unit provides products and services in crop protection, seeds and traits, digital farming, fruits and vegetables, and environmental science solutions aimed at sustainable agriculture. Bayer maintains a global footprint with operations across North America, Europe, Asia-Pacific, Latin America, Africa, and the Middle East. Founded in 1863, Bayer continues to be a leader in pharmaceutical and agricultural innovation. In recent major developments during 2024 and 2025, Bayer has continued its corporate restructuring under the Dynamic Shared Ownership operating model introduced in early 2024, aiming to increase agility and operational efficiency. This has involved workforce reductions of approximately 12,000 jobs worldwide, focusing on management and administrative layers, with expected annual cost savings of up to 2 billion euros by 2026. Bayer has advanced a differentiated pharmaceutical pipeline targeting oncology, cardiovascular diseases, neurology, rare diseases, and immunology, with anticipated product launches including treatments for heart failure and hormone-free solutions for menopausal symptoms by the end of 2025. It also pursues growth in cell and gene therapy and targeted radiopharmaceuticals. On the Crop Science front, Bayer is rolling out innovations such as the Preceon Smart Corn System and new herbicides while focusing on digital farming and environmental sustainability. Despite pressure from investors to divest or break up its business units, Bayer has postponed any structural separation, instead emphasizing portfolio management and strategic alliances. The company also navigates significant legal provisions related to litigation over its Roundup weedkiller product. Overall, Bayer maintains a strong commitment to research and development to support its leadership in life sciences globally.
Company News
Bayer to Present New Cardiac Amyloidosis and Heart Failure Data at the Heart Failure Society of America (HFSA) Annual Scientific Meeting
Bayer Seeks Kerendia Label Expansion in Non-Diabetic CKD
Actress and Menopause Advocate Melissa Joan Hart Partners with Bayer to Raise Awareness about Lynkuet® (elinzanetant), a Prescription Treatment for Moderate to Severe Hot Flashes due to Menopause
U.S. FDA Accepts Bayer's Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes
BAYRY vs. RHHBY: Which Stock Should Value Investors Buy Now?
Bayer to Invest $2.2 Billion in U.S. Pharma Manufacturing Expansion
Bayer to invest $2.2 billion in new US pharma site
Bayer to Invest 2.2 Billion U.S. Dollars in a New Manufacturing Site in the United States
Bayer faces trial test of remaining Roundup claims after US Supreme Court win
Bayer Sells Cancer Drug to Gruenenthal for Up to $431 Million
FDA Approves Label Expansion of BAYRY's Kidney Disease Drug Kerendia
Bayer's KERENDIA® (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes
Bayer's Monsanto unit urges Missouri judge to approve $7.25 billion Roundup settlement
Bayer faces pivotal test of $7.25 billion Roundup settlement in Missouri court
Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road
Bayer Secures FDA Nod for Sevabertinib's First-Line Use in NSCLC
U.S. FDA Grants Accelerated Approval to Bayer's HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer
Bayer and Neste Close Commercial Agreement to Jointly Scale newgold® Winter Canola for Biofuels Production
BAYER INITIATES PHASE II STUDY OF INVESTIGATIONAL GIRK4 INHIBITOR IN PATIENTS WITH ATRIAL FIBRILLATION
Bayer Aktiengesellschaft (BAYRY) Discusses Innovation Strategy and Progress on Five-Year Growth Framework in Crop Science Division Transcript